Annual Income Statements for Omega Healthcare Investors
This table shows Omega Healthcare Investors' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.
Quarterly Income Statements for Omega Healthcare Investors
This table shows Omega Healthcare Investors' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
Q2 2025 |
Q3 2025 |
Q4 2025 |
Q1 2026 |
| Net Income / (Loss) Attributable to Common Shareholders |
|
91 |
55 |
67 |
114 |
112 |
113 |
109 |
137 |
180 |
165 |
151 |
| Consolidated Net Income / (Loss) |
|
94 |
57 |
69 |
117 |
115 |
116 |
112 |
140 |
185 |
172 |
159 |
| Net Income / (Loss) Continuing Operations |
|
94 |
57 |
69 |
117 |
115 |
116 |
112 |
140 |
185 |
172 |
159 |
| Total Pre-Tax Income |
|
97 |
62 |
72 |
119 |
111 |
119 |
115 |
147 |
191 |
171 |
160 |
| Total Revenue |
|
183 |
179 |
184 |
212 |
221 |
219 |
235 |
230 |
282 |
229 |
276 |
| Net Interest Income / (Expense) |
|
-28 |
-28 |
-22 |
-16 |
-15 |
-12 |
-9.16 |
-9.90 |
-13 |
-7.56 |
-4.60 |
| Total Interest Income |
|
31 |
32 |
36 |
38 |
40 |
43 |
43 |
43 |
45 |
44 |
45 |
| Loans and Leases Interest Income |
|
31 |
32 |
36 |
38 |
40 |
43 |
43 |
43 |
45 |
44 |
45 |
| Total Interest Expense |
|
59 |
59 |
58 |
54 |
55 |
55 |
52 |
53 |
58 |
52 |
50 |
| Long-Term Debt Interest Expense |
|
59 |
59 |
58 |
54 |
55 |
55 |
52 |
53 |
58 |
52 |
50 |
| Total Non-Interest Income |
|
211 |
207 |
206 |
228 |
236 |
231 |
244 |
240 |
295 |
237 |
281 |
| Other Service Charges |
|
1.21 |
-0.83 |
0.54 |
0.39 |
4.60 |
-4.54 |
1.49 |
0.31 |
2.24 |
8.98 |
0.53 |
| Net Realized & Unrealized Capital Gains on Investments |
|
- |
- |
-1.39 |
13 |
-0.24 |
- |
10 |
- |
28 |
- |
3.02 |
| Other Non-Interest Income |
|
210 |
208 |
207 |
214 |
231 |
235 |
232 |
239 |
265 |
266 |
277 |
| Provision for Credit Losses |
|
2.73 |
33 |
8.47 |
-14 |
-9.06 |
-0.72 |
5.09 |
-4.77 |
-3.91 |
5.92 |
-3.29 |
| Total Non-Interest Expense |
|
89 |
96 |
108 |
110 |
118 |
106 |
118 |
101 |
111 |
73 |
121 |
| Other Operating Expenses |
|
24 |
22 |
25 |
26 |
25 |
26 |
35 |
27 |
27 |
29 |
30 |
| Depreciation Expense |
|
81 |
76 |
75 |
74 |
77 |
79 |
80 |
81 |
82 |
83 |
84 |
| Impairment Charge |
|
28 |
3.95 |
5.29 |
8.18 |
8.62 |
1.74 |
1.24 |
14 |
1.14 |
6.02 |
0.39 |
| Restructuring Charge |
|
0.12 |
4.16 |
2.60 |
1.78 |
6.44 |
0.80 |
1.46 |
2.01 |
0.59 |
0.15 |
1.11 |
| Other Special Charges |
|
-44 |
-9.71 |
- |
- |
- |
- |
0.00 |
-23 |
- |
- |
5.43 |
| Nonoperating Income / (Expense), net |
|
5.40 |
12 |
3.99 |
3.15 |
-1.18 |
4.39 |
3.05 |
14 |
17 |
21 |
1.08 |
| Income Tax Expense |
|
1.76 |
4.16 |
2.58 |
1.98 |
3.32 |
2.98 |
3.61 |
4.53 |
4.48 |
2.13 |
5.11 |
| Other Gains / (Losses), net |
|
-1.35 |
-1.14 |
0.10 |
0.14 |
6.88 |
0.80 |
1.08 |
-2.19 |
-1.91 |
2.80 |
3.76 |
| Net Income / (Loss) Attributable to Noncontrolling Interest |
|
2.53 |
1.52 |
1.99 |
3.22 |
3.15 |
3.12 |
3.03 |
3.88 |
5.24 |
7.14 |
7.53 |
| Basic Earnings per Share |
|
$0.37 |
$0.24 |
$0.27 |
$0.46 |
$0.43 |
$0.41 |
$0.34 |
$0.46 |
$0.60 |
$0.56 |
$0.47 |
| Weighted Average Basic Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Diluted Earnings per Share |
|
$0.37 |
$0.23 |
$0.27 |
$0.45 |
$0.42 |
$0.41 |
$0.33 |
$0.46 |
$0.59 |
$0.56 |
$0.47 |
| Weighted Average Diluted Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Weighted Average Basic & Diluted Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Cash Dividends to Common per Share |
|
$0.67 |
- |
$0.67 |
$0.67 |
$0.67 |
- |
$0.67 |
$0.67 |
$0.67 |
- |
$0.67 |
Annual Cash Flow Statements for Omega Healthcare Investors
This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
| Net Change in Cash & Equivalents |
|
-14 |
87 |
-10 |
-85 |
22 |
134 |
-143 |
276 |
144 |
104 |
-494 |
| Net Cash From Operating Activities |
|
-17 |
625 |
578 |
499 |
554 |
708 |
722 |
626 |
618 |
749 |
879 |
| Net Cash From Continuing Operating Activities |
|
449 |
625 |
578 |
499 |
554 |
708 |
723 |
626 |
618 |
749 |
879 |
| Net Income / (Loss) Continuing Operations |
|
0.00 |
383 |
105 |
294 |
352 |
164 |
428 |
439 |
249 |
418 |
609 |
| Consolidated Net Income / (Loss) |
|
- |
383 |
105 |
294 |
352 |
164 |
428 |
439 |
249 |
418 |
609 |
| Provision For Loan Losses |
|
7.87 |
9.85 |
15 |
0.00 |
11 |
185 |
117 |
193 |
45 |
-15 |
2.34 |
| Depreciation Expense |
|
211 |
267 |
288 |
281 |
302 |
330 |
342 |
332 |
320 |
305 |
325 |
| Amortization Expense |
|
22 |
-2.53 |
7.80 |
-1.75 |
3.66 |
-2.58 |
34 |
7.68 |
14 |
12 |
0.97 |
| Non-Cash Adjustments to Reconcile Net Income |
|
209 |
-32 |
227 |
-7.73 |
-37 |
35 |
-105 |
-303 |
47 |
40 |
-6.26 |
| Changes in Operating Assets and Liabilities, net |
|
0.15 |
-1.03 |
-64 |
-66 |
-77 |
-1.87 |
-93 |
-44 |
-57 |
-10 |
-53 |
| Net Cash From Investing Activities |
|
-397 |
-1,114 |
-285 |
-173 |
-379 |
-89 |
-524 |
443 |
-0.77 |
-671 |
-540 |
| Net Cash From Continuing Investing Activities |
|
-397 |
-1,114 |
-285 |
-173 |
-379 |
-89 |
-524 |
443 |
-0.77 |
-671 |
-540 |
| Purchase of Property, Leasehold Improvements and Equipment |
|
-191 |
-109 |
-124 |
-169 |
-53 |
-106 |
-45 |
-47 |
-38 |
-38 |
-81 |
| Purchase of Investment Securities |
|
-380 |
-1,332 |
-566 |
-556 |
-603 |
-344 |
-867 |
-602 |
-684 |
-871 |
-974 |
| Divestitures |
|
85 |
1.32 |
15 |
5.47 |
9.08 |
6.29 |
18 |
3.33 |
8.81 |
1.02 |
13 |
| Sale and/or Maturity of Investments |
|
89 |
326 |
391 |
547 |
459 |
357 |
476 |
1,105 |
750 |
303 |
529 |
| Other Investing Activities, net |
|
- |
- |
- |
- |
-132 |
- |
-89 |
-16 |
-38 |
-66 |
-27 |
| Net Cash From Financing Activities |
|
-65 |
576 |
-304 |
-411 |
-154 |
-486 |
-341 |
-789 |
-473 |
26 |
-838 |
| Net Cash From Continuing Financing Activities |
|
-65 |
576 |
-304 |
-411 |
-154 |
-486 |
-341 |
-789 |
-473 |
26 |
-836 |
| Issuance of Debt |
|
3,664 |
2,352 |
3,034 |
1,291 |
2,002 |
1,852 |
2,275 |
597 |
507 |
658 |
1,312 |
| Issuance of Common Equity |
|
590 |
260 |
59 |
122 |
516 |
152 |
274 |
8.11 |
336 |
1,236 |
607 |
| Repayment of Debt |
|
-3,923 |
-1,537 |
-2,869 |
-1,270 |
-2,086 |
-1,856 |
-2,227 |
-590 |
-739 |
-1,152 |
-1,924 |
| Payment of Dividends |
|
-370 |
-453 |
-503 |
-529 |
-585 |
-612 |
-663 |
-653 |
-670 |
-715 |
-824 |
| Other Financing Activities, Net |
|
-27 |
-45 |
-25 |
-25 |
0.00 |
-21 |
-0.08 |
-9.62 |
92 |
-0.14 |
-6.25 |
| Other Net Changes in Cash |
|
-0.22 |
0.08 |
- |
- |
0.87 |
- |
0.01 |
-2.90 |
0.43 |
-0.58 |
5.33 |
Quarterly Cash Flow Statements for Omega Healthcare Investors
This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
Q2 2025 |
Q3 2025 |
Q4 2025 |
Q1 2026 |
| Net Change in Cash & Equivalents |
|
201 |
-113 |
-82 |
-324 |
321 |
188 |
-145 |
369 |
2.42 |
-720 |
-1.24 |
| Net Cash From Operating Activities |
|
171 |
165 |
151 |
184 |
185 |
229 |
182 |
239 |
227 |
231 |
216 |
| Net Cash From Continuing Operating Activities |
|
171 |
165 |
151 |
184 |
185 |
229 |
182 |
239 |
227 |
231 |
216 |
| Net Income / (Loss) Continuing Operations |
|
94 |
57 |
69 |
117 |
115 |
116 |
112 |
140 |
185 |
172 |
159 |
| Consolidated Net Income / (Loss) |
|
94 |
57 |
69 |
117 |
115 |
116 |
112 |
140 |
185 |
172 |
159 |
| Provision For Loan Losses |
|
9.97 |
33 |
8.47 |
-14 |
-7.93 |
2.32 |
5.09 |
23 |
-31 |
5.92 |
-3.29 |
| Depreciation Expense |
|
81 |
76 |
75 |
74 |
77 |
79 |
80 |
81 |
82 |
83 |
84 |
| Amortization Expense |
|
1.35 |
3.65 |
4.96 |
3.04 |
0.78 |
2.21 |
1.38 |
1.02 |
1.06 |
-2.49 |
3.40 |
| Non-Cash Adjustments to Reconcile Net Income |
|
-7.88 |
-2.48 |
13 |
2.19 |
9.66 |
13 |
15 |
-13 |
1.79 |
-9.29 |
4.31 |
| Changes in Operating Assets and Liabilities, net |
|
-7.12 |
-1.30 |
-19 |
1.73 |
-9.78 |
16 |
-31 |
7.88 |
-12 |
-18 |
-32 |
| Net Cash From Investing Activities |
|
73 |
111 |
-47 |
-209 |
-133 |
-282 |
19 |
-464 |
-84 |
-12 |
-270 |
| Net Cash From Continuing Investing Activities |
|
73 |
111 |
-47 |
-209 |
-133 |
-282 |
19 |
-464 |
-84 |
-12 |
-270 |
| Purchase of Property, Leasehold Improvements and Equipment |
|
-10 |
-59 |
-21 |
-35 |
-25 |
-25 |
-35 |
2.31 |
-21 |
-27 |
-13 |
| Acquisitions |
|
- |
- |
0.00 |
- |
- |
- |
-30 |
- |
- |
- |
0.00 |
| Purchase of Investment Securities |
|
-128 |
-218 |
-53 |
-252 |
-182 |
-377 |
-100 |
-566 |
-175 |
-133 |
-333 |
| Divestitures |
|
1.88 |
5.79 |
0.94 |
0.31 |
1.59 |
-1.82 |
1.16 |
0.31 |
8.50 |
2.94 |
3.40 |
| Sale and/or Maturity of Investments |
|
213 |
360 |
26 |
77 |
72 |
122 |
184 |
99 |
101 |
145 |
73 |
| Net Cash From Financing Activities |
|
-42 |
-390 |
-186 |
-299 |
268 |
243 |
-348 |
589 |
-139 |
-940 |
54 |
| Net Cash From Continuing Financing Activities |
|
-42 |
-390 |
-186 |
-299 |
268 |
243 |
-348 |
589 |
-139 |
-938 |
54 |
| Issuance of Debt |
|
427 |
- |
- |
- |
179 |
- |
0.00 |
- |
- |
641 |
719 |
| Issuance of Common Equity |
|
126 |
8.66 |
32 |
243 |
526 |
434 |
261 |
257 |
89 |
-0.04 |
105 |
| Repayment of Debt |
|
-425 |
-228 |
-43 |
-849 |
-258 |
-2.63 |
-401 |
-133 |
-20 |
-1,370 |
-536 |
| Payment of Dividends |
|
-170 |
-170 |
-175 |
-172 |
-180 |
-188 |
-208 |
-202 |
-206 |
-209 |
-220 |
| Other Financing Activities, Net |
|
0.00 |
- |
- |
0.55 |
- |
-0.68 |
0.00 |
- |
-2.09 |
-0.48 |
-13 |
| Other Net Changes in Cash |
|
-0.35 |
- |
- |
- |
- |
- |
1.82 |
3.84 |
-1.45 |
1.11 |
-1.05 |
Annual Balance Sheets for Omega Healthcare Investors
This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
| Total Assets |
|
7,990 |
8,949 |
8,773 |
17,182 |
9,796 |
9,497 |
9,638 |
9,405 |
9,117 |
9,898 |
10,049 |
| Cash and Due from Banks |
|
5.42 |
94 |
86 |
21 |
24 |
164 |
21 |
297 |
443 |
518 |
27 |
| Restricted Cash |
|
15 |
- |
11 |
2.74 |
9.26 |
4.02 |
3.88 |
3.54 |
1.92 |
30 |
28 |
| Trading Account Securities |
|
- |
49 |
37 |
62 |
200 |
201 |
195 |
179 |
188 |
89 |
414 |
| Loans and Leases, Net of Allowance |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Premises and Equipment, Net |
|
5,725 |
6,326 |
6,279 |
-3,125 |
7,199 |
6,705 |
6,847 |
6,537 |
5,903 |
6,339 |
6,703 |
| Goodwill |
|
646 |
643 |
645 |
1,288 |
644 |
652 |
651 |
643 |
644 |
644 |
645 |
| Other Assets |
|
920 |
1,198 |
1,045 |
1,392 |
946 |
887 |
1,921 |
1,745 |
1,938 |
2,278 |
2,233 |
| Total Liabilities & Shareholders' Equity |
|
7,990 |
8,949 |
8,773 |
17,182 |
9,796 |
9,497 |
9,638 |
9,405 |
9,117 |
9,898 |
10,049 |
| Total Liabilities |
|
3,889 |
4,737 |
4,885 |
4,667 |
5,460 |
5,461 |
5,530 |
5,602 |
5,355 |
5,167 |
4,609 |
| Short-Term Debt |
|
230 |
190 |
290 |
313 |
125 |
101 |
0.00 |
19 |
20 |
0.00 |
242 |
| Long-Term Debt |
|
3,310 |
4,177 |
4,282 |
4,327 |
5,011 |
5,068 |
5,254 |
5,268 |
5,047 |
4,839 |
4,014 |
| Other Long-Term Liabilities |
|
15 |
370 |
18 |
27 |
323 |
292 |
277 |
315 |
288 |
328 |
353 |
| Total Equity & Noncontrolling Interests |
|
4,101 |
4,212 |
3,888 |
3,764 |
4,337 |
4,037 |
4,108 |
3,803 |
3,762 |
4,731 |
5,440 |
| Total Preferred & Common Equity |
|
3,738 |
3,859 |
3,555 |
3,444 |
4,135 |
3,842 |
3,907 |
3,609 |
3,575 |
4,537 |
5,181 |
| Preferred Stock |
|
- |
- |
- |
- |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Common Equity |
|
3,738 |
3,859 |
3,555 |
3,444 |
4,135 |
3,842 |
3,907 |
3,609 |
3,575 |
4,537 |
5,181 |
| Common Stock |
|
4,628 |
4,881 |
4,956 |
5,095 |
6,015 |
6,176 |
6,451 |
6,338 |
6,696 |
7,944 |
8,723 |
| Retained Earnings |
|
-882 |
-968 |
-1,371 |
-1,609 |
-1,840 |
-2,321 |
-2,542 |
-2,749 |
-3,150 |
-3,430 |
-3,620 |
| Accumulated Other Comprehensive Income / (Loss) |
|
-8.71 |
-54 |
-30 |
-42 |
-40 |
-13 |
-2.20 |
20 |
29 |
23 |
79 |
| Noncontrolling Interest |
|
363 |
353 |
333 |
320 |
201 |
195 |
201 |
194 |
188 |
194 |
259 |
Quarterly Balance Sheets for Omega Healthcare Investors
This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.
| Metric |
|
Q3 2022 |
Q1 2023 |
Q2 2023 |
Q3 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q1 2025 |
Q2 2025 |
Q3 2025 |
Q1 2026 |
| Total Assets |
|
9,476 |
9,290 |
9,404 |
9,425 |
9,012 |
8,849 |
9,572 |
9,706 |
10,546 |
10,596 |
10,235 |
| Cash and Due from Banks |
|
135 |
245 |
351 |
555 |
362 |
35 |
342 |
368 |
734 |
737 |
26 |
| Restricted Cash |
|
3.32 |
3.34 |
5.82 |
3.21 |
1.25 |
3.94 |
18 |
36 |
38 |
38 |
27 |
| Trading Account Securities |
|
177 |
181 |
192 |
188 |
186 |
185 |
93 |
89 |
85 |
150 |
508 |
| Loans and Leases, Net of Allowance |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Premises and Equipment, Net |
|
6,462 |
6,438 |
6,489 |
6,193 |
5,834 |
5,877 |
6,292 |
6,333 |
6,795 |
6,742 |
6,470 |
| Goodwill |
|
649 |
644 |
644 |
643 |
644 |
644 |
645 |
644 |
645 |
645 |
644 |
| Other Assets |
|
1,380 |
1,779 |
1,723 |
1,844 |
1,985 |
2,103 |
2,183 |
2,236 |
2,248 |
2,284 |
2,559 |
| Total Liabilities & Shareholders' Equity |
|
9,476 |
9,290 |
9,404 |
9,425 |
9,012 |
8,849 |
9,572 |
9,706 |
10,546 |
10,596 |
10,235 |
| Total Liabilities |
|
5,580 |
5,605 |
5,591 |
5,568 |
5,311 |
4,948 |
5,172 |
4,774 |
5,357 |
5,352 |
4,780 |
| Short-Term Debt |
|
18 |
20 |
20 |
20 |
20 |
70 |
0.00 |
0.00 |
0.00 |
- |
425 |
| Long-Term Debt |
|
5,267 |
5,268 |
5,267 |
5,272 |
5,008 |
4,590 |
4,858 |
4,446 |
5,000 |
4,995 |
4,016 |
| Other Long-Term Liabilities |
|
295 |
317 |
305 |
277 |
283 |
287 |
313 |
327 |
357 |
357 |
338 |
| Total Equity & Noncontrolling Interests |
|
3,895 |
3,686 |
3,813 |
3,857 |
3,701 |
3,901 |
4,400 |
4,932 |
5,189 |
5,244 |
5,455 |
| Total Preferred & Common Equity |
|
3,698 |
3,497 |
3,624 |
3,669 |
3,514 |
3,711 |
4,208 |
4,741 |
4,988 |
5,036 |
5,191 |
| Preferred Stock |
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Common Equity |
|
3,698 |
3,497 |
3,624 |
3,669 |
3,514 |
3,711 |
4,208 |
4,741 |
4,988 |
5,036 |
5,191 |
| Common Stock |
|
6,329 |
6,346 |
6,550 |
6,682 |
6,730 |
6,977 |
7,507 |
8,208 |
8,460 |
8,546 |
8,805 |
| Retained Earnings |
|
-2,637 |
-2,870 |
-2,968 |
-3,041 |
-3,248 |
-3,300 |
-3,362 |
-3,510 |
-3,568 |
-3,587 |
-3,668 |
| Accumulated Other Comprehensive Income / (Loss) |
|
6.24 |
22 |
41 |
28 |
32 |
34 |
63 |
43 |
97 |
77 |
54 |
| Noncontrolling Interest |
|
197 |
189 |
188 |
188 |
187 |
190 |
192 |
191 |
201 |
208 |
264 |
Annual Metrics And Ratios for Omega Healthcare Investors
This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.
| Metric |
|
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
| Growth Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Profitability Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Valuation Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Leverage & Solvency |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Liquidity Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Cash Flow Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Efficiency Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Capital & Investment Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Earnings Adjustments |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Adjusted Basic Earnings per Share |
|
$1.30 |
$1.91 |
$0.51 |
$1.41 |
$1.60 |
$0.70 |
$1.76 |
$1.81 |
$1.01 |
$1.57 |
$1.96 |
| Adjusted Weighted Average Basic Shares Outstanding |
|
172.24M |
191.78M |
197.74M |
618.32M |
213.40M |
231.78M |
239.11M |
234.27M |
245.30M |
281.84M |
295.57M |
| Adjusted Diluted Earnings per Share |
|
$1.29 |
$1.90 |
$0.51 |
$1.40 |
$1.58 |
$0.70 |
$1.75 |
$1.80 |
$1.00 |
$1.55 |
$1.94 |
| Adjusted Weighted Average Diluted Shares Outstanding |
|
180.51M |
201.64M |
206.79M |
419.42M |
222.13M |
231.78M |
239.11M |
234.27M |
245.30M |
281.84M |
295.57M |
| Adjusted Basic & Diluted Earnings per Share |
|
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.60 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Adjusted Weighted Average Basic & Diluted Shares Outstanding |
|
188.13M |
196.74M |
198.59M |
209.71M |
226.81M |
231.78M |
239.11M |
234.27M |
245.30M |
281.84M |
295.57M |
| Debt Service Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Payout Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Quarterly Metrics And Ratios for Omega Healthcare Investors
This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.
| Metric |
|
Q3 2023 |
Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 |
Q1 2025 |
Q2 2025 |
Q3 2025 |
Q4 2025 |
Q1 2026 |
| DEI Shares Outstanding |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
295,570,000.00 |
| DEI Adjusted Shares Outstanding |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
295,570,000.00 |
| DEI Earnings Per Adjusted Shares Outstanding |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
0.54 |
| Growth Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Revenue Growth |
|
-17.50% |
-39.61% |
19.48% |
3.29% |
20.65% |
22.46% |
27.43% |
8.46% |
27.43% |
- |
17.75% |
| EBITDA Growth |
|
-7.60% |
-3.57% |
37.86% |
31.59% |
9.66% |
50.69% |
30.84% |
11.05% |
34.34% |
- |
27.79% |
| EBIT Growth |
|
-10.79% |
1.57% |
128.42% |
86.49% |
22.84% |
127.91% |
64.43% |
15.27% |
55.09% |
- |
42.40% |
| NOPAT Growth |
|
-11.37% |
-3.20% |
112.31% |
88.32% |
21.38% |
138.22% |
65.19% |
13.61% |
56.10% |
- |
42.34% |
| Net Income Growth |
|
-10.62% |
21.02% |
88.21% |
90.31% |
22.37% |
106.05% |
61.60% |
19.99% |
60.95% |
- |
41.51% |
| EPS Growth |
|
-13.95% |
15.00% |
80.00% |
80.00% |
13.51% |
78.26% |
22.22% |
2.22% |
40.48% |
- |
42.42% |
| Operating Cash Flow Growth |
|
2.50% |
7.35% |
36.02% |
8.06% |
8.11% |
38.79% |
20.12% |
29.96% |
22.62% |
- |
18.44% |
| Free Cash Flow Firm Growth |
|
-71.84% |
-3.96% |
-61.45% |
205.10% |
-100.59% |
-304.61% |
-274.57% |
-329.85% |
-112,641.83% |
- |
32.73% |
| Invested Capital Growth |
|
-0.34% |
-2.87% |
-2.73% |
-5.92% |
1.20% |
8.38% |
7.44% |
19.02% |
10.59% |
- |
5.52% |
| Revenue Q/Q Growth |
|
-4.77% |
-2.40% |
-4.22% |
4.21% |
11.23% |
-0.93% |
7.09% |
-2.12% |
22.71% |
- |
20.55% |
| EBITDA Q/Q Growth |
|
18.44% |
-25.50% |
1.56% |
26.92% |
-1.29% |
2.38% |
-1.17% |
11.50% |
19.88% |
- |
7.06% |
| EBIT Q/Q Growth |
|
47.57% |
-45.28% |
3.81% |
58.34% |
-2.80% |
1.53% |
-2.37% |
19.63% |
30.78% |
- |
5.99% |
| NOPAT Q/Q Growth |
|
48.79% |
-48.02% |
7.30% |
61.51% |
-4.09% |
2.02% |
-3.01% |
19.72% |
31.77% |
- |
3.89% |
| Net Income Q/Q Growth |
|
52.64% |
-39.81% |
22.69% |
68.83% |
-1.85% |
1.35% |
-3.78% |
25.36% |
31.66% |
- |
-7.79% |
| EPS Q/Q Growth |
|
48.00% |
-37.84% |
17.39% |
66.67% |
-6.67% |
-2.38% |
-19.51% |
39.39% |
28.26% |
- |
-16.07% |
| Operating Cash Flow Q/Q Growth |
|
0.38% |
-3.53% |
-8.19% |
21.54% |
0.42% |
23.84% |
-20.53% |
31.50% |
-5.25% |
- |
-6.56% |
| Free Cash Flow Firm Q/Q Growth |
|
-43.11% |
152.69% |
-3.35% |
106.83% |
-100.11% |
-87,442.62% |
13.87% |
-176.80% |
45.98% |
- |
-1,818.34% |
| Invested Capital Q/Q Growth |
|
0.54% |
-3.49% |
-1.14% |
-1.92% |
8.15% |
3.36% |
-2.00% |
8.65% |
0.48% |
- |
2.06% |
| Profitability Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBITDA Margin |
|
94.82% |
72.38% |
79.73% |
97.12% |
86.18% |
89.06% |
82.19% |
93.62% |
91.46% |
- |
89.20% |
| EBIT Margin |
|
49.99% |
28.03% |
38.33% |
58.24% |
50.90% |
52.16% |
47.55% |
58.12% |
61.94% |
- |
57.50% |
| Profit (Net Income) Margin |
|
51.24% |
31.60% |
36.35% |
58.90% |
51.97% |
53.17% |
47.77% |
61.18% |
65.65% |
- |
57.41% |
| Tax Burden Percent |
|
96.80% |
91.43% |
96.54% |
98.45% |
103.20% |
98.16% |
97.79% |
95.44% |
96.66% |
- |
99.16% |
| Interest Burden Percent |
|
105.90% |
123.32% |
98.25% |
102.72% |
98.95% |
103.84% |
102.73% |
110.30% |
109.64% |
- |
100.68% |
| Effective Tax Rate |
|
1.81% |
6.73% |
3.59% |
1.67% |
2.98% |
2.51% |
3.15% |
3.08% |
2.34% |
- |
3.19% |
| Return on Invested Capital (ROIC) |
|
2.53% |
2.08% |
3.20% |
5.01% |
4.34% |
4.59% |
4.48% |
5.40% |
5.95% |
- |
5.87% |
| ROIC Less NNEP Spread (ROIC-NNEP) |
|
2.60% |
2.27% |
3.17% |
5.07% |
4.46% |
4.69% |
4.56% |
5.63% |
6.24% |
- |
5.98% |
| Return on Net Nonoperating Assets (RNNOA) |
|
3.55% |
3.11% |
4.43% |
6.54% |
5.48% |
5.47% |
5.01% |
5.98% |
6.38% |
- |
5.12% |
| Return on Equity (ROE) |
|
6.07% |
5.19% |
7.63% |
11.55% |
9.82% |
10.05% |
9.48% |
11.38% |
12.33% |
- |
10.99% |
| Cash Return on Invested Capital (CROIC) |
|
2.88% |
5.48% |
6.01% |
9.95% |
2.71% |
-3.64% |
-2.23% |
-12.43% |
-4.68% |
- |
0.87% |
| Operating Return on Assets (OROA) |
|
2.49% |
2.16% |
3.21% |
4.93% |
4.34% |
4.55% |
4.47% |
5.38% |
5.89% |
- |
5.86% |
| Return on Assets (ROA) |
|
2.56% |
2.44% |
3.04% |
4.98% |
4.43% |
4.64% |
4.49% |
5.67% |
6.24% |
- |
5.85% |
| Return on Common Equity (ROCE) |
|
5.77% |
4.93% |
7.24% |
10.98% |
9.37% |
9.60% |
9.07% |
10.89% |
11.82% |
- |
10.51% |
| Return on Equity Simple (ROE_SIMPLE) |
|
6.51% |
0.00% |
8.01% |
9.08% |
8.50% |
0.00% |
9.71% |
9.70% |
11.00% |
- |
12.64% |
| Net Operating Profit after Tax (NOPAT) |
|
90 |
47 |
70 |
114 |
109 |
111 |
108 |
129 |
170 |
- |
154 |
| NOPAT Margin |
|
49.08% |
26.14% |
36.95% |
57.27% |
49.38% |
50.85% |
46.05% |
56.33% |
60.49% |
- |
55.67% |
| Net Nonoperating Expense Percent (NNEP) |
|
-0.07% |
-0.19% |
0.02% |
-0.07% |
-0.11% |
-0.10% |
-0.09% |
-0.23% |
-0.29% |
- |
-0.11% |
| SG&A Expenses to Revenue |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
- |
0.00% |
| Operating Expenses to Revenue |
|
48.52% |
53.57% |
57.23% |
48.89% |
53.20% |
48.17% |
50.28% |
43.96% |
39.44% |
- |
43.69% |
| Earnings before Interest and Taxes (EBIT) |
|
92 |
50 |
73 |
116 |
113 |
114 |
112 |
133 |
175 |
- |
159 |
| Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
|
174 |
129 |
152 |
193 |
191 |
195 |
193 |
215 |
258 |
- |
246 |
| Valuation Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Price to Book Value (P/BV) |
|
2.04 |
1.91 |
2.12 |
2.24 |
2.49 |
2.21 |
2.26 |
2.13 |
2.47 |
- |
2.49 |
| Price to Tangible Book Value (P/TBV) |
|
2.47 |
2.33 |
2.60 |
2.71 |
2.95 |
2.58 |
2.62 |
2.44 |
2.84 |
- |
2.85 |
| Price to Revenue (P/Rev) |
|
15.85 |
9.55 |
9.74 |
10.77 |
12.96 |
12.10 |
12.19 |
11.81 |
12.99 |
- |
12.74 |
| Price to Earnings (P/E) |
|
32.11 |
28.16 |
27.26 |
25.38 |
30.16 |
24.70 |
23.96 |
22.53 |
23.12 |
- |
20.49 |
| Dividend Yield |
|
8.78% |
9.63% |
8.80% |
7.96% |
6.58% |
7.21% |
7.04% |
7.31% |
6.35% |
- |
6.12% |
| Earnings Yield |
|
3.11% |
3.55% |
3.67% |
3.94% |
3.32% |
4.05% |
4.17% |
4.44% |
4.33% |
- |
4.88% |
| Enterprise Value to Invested Capital (EV/IC) |
|
1.35 |
1.32 |
1.41 |
1.53 |
1.64 |
1.52 |
1.60 |
1.48 |
1.65 |
- |
1.78 |
| Enterprise Value to Revenue (EV/Rev) |
|
26.29 |
16.28 |
16.08 |
17.00 |
18.75 |
17.50 |
17.00 |
16.74 |
17.61 |
- |
17.31 |
| Enterprise Value to EBITDA (EV/EBITDA) |
|
21.94 |
20.76 |
19.78 |
19.63 |
22.15 |
19.87 |
19.28 |
18.85 |
19.55 |
- |
18.55 |
| Enterprise Value to EBIT (EV/EBIT) |
|
52.73 |
49.32 |
41.42 |
37.40 |
40.84 |
34.93 |
32.58 |
31.52 |
31.32 |
- |
28.55 |
| Enterprise Value to NOPAT (EV/NOPAT) |
|
53.42 |
50.55 |
42.90 |
38.56 |
42.23 |
35.86 |
33.44 |
32.47 |
32.20 |
- |
29.26 |
| Enterprise Value to Operating Cash Flow (EV/OCF) |
|
20.44 |
18.83 |
18.71 |
19.55 |
22.15 |
19.38 |
19.19 |
18.00 |
19.25 |
- |
19.30 |
| Enterprise Value to Free Cash Flow (EV/FCFF) |
|
47.01 |
23.71 |
23.15 |
14.94 |
60.82 |
0.00 |
0.00 |
0.00 |
0.00 |
- |
210.32 |
| Leverage & Solvency |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Debt to Equity |
|
1.37 |
1.35 |
1.36 |
1.19 |
1.10 |
1.02 |
0.90 |
0.96 |
0.95 |
- |
0.81 |
| Long-Term Debt to Equity |
|
1.37 |
1.34 |
1.35 |
1.18 |
1.10 |
1.02 |
0.90 |
0.96 |
0.95 |
- |
0.74 |
| Financial Leverage |
|
1.36 |
1.37 |
1.40 |
1.29 |
1.23 |
1.17 |
1.10 |
1.06 |
1.02 |
- |
0.86 |
| Leverage Ratio |
|
2.44 |
2.45 |
2.48 |
2.37 |
2.30 |
2.24 |
2.17 |
2.13 |
2.09 |
- |
1.92 |
| Compound Leverage Factor |
|
2.58 |
3.02 |
2.43 |
2.43 |
2.28 |
2.32 |
2.23 |
2.35 |
2.29 |
- |
1.93 |
| Debt to Total Capital |
|
57.84% |
57.39% |
57.60% |
54.44% |
52.47% |
50.56% |
47.41% |
49.07% |
48.78% |
- |
44.88% |
| Short-Term Debt to Total Capital |
|
0.21% |
0.23% |
0.23% |
0.82% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
- |
4.29% |
| Long-Term Debt to Total Capital |
|
57.62% |
57.16% |
57.37% |
53.62% |
52.47% |
50.56% |
47.41% |
49.07% |
48.78% |
- |
40.58% |
| Preferred Equity to Total Capital |
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
- |
0.00% |
| Noncontrolling Interests to Total Capital |
|
2.06% |
2.13% |
2.14% |
2.22% |
2.08% |
2.03% |
2.04% |
1.97% |
2.03% |
- |
2.66% |
| Common Equity to Total Capital |
|
40.10% |
40.48% |
40.26% |
43.35% |
45.45% |
47.41% |
50.55% |
48.96% |
49.19% |
- |
52.46% |
| Debt to EBITDA |
|
9.36 |
9.04 |
8.08 |
6.97 |
7.09 |
6.62 |
5.73 |
6.27 |
5.78 |
- |
4.68 |
| Net Debt to EBITDA |
|
8.38 |
8.25 |
7.50 |
6.91 |
6.56 |
5.87 |
5.21 |
5.30 |
4.89 |
- |
4.62 |
| Long-Term Debt to EBITDA |
|
9.33 |
9.01 |
8.05 |
6.87 |
7.09 |
6.62 |
5.73 |
6.27 |
5.78 |
- |
4.23 |
| Debt to NOPAT |
|
22.80 |
22.03 |
17.52 |
13.69 |
13.51 |
11.95 |
9.93 |
10.80 |
9.53 |
- |
7.38 |
| Net Debt to NOPAT |
|
20.40 |
20.09 |
16.26 |
13.58 |
12.51 |
10.59 |
9.03 |
9.13 |
8.05 |
- |
7.29 |
| Long-Term Debt to NOPAT |
|
22.72 |
21.94 |
17.45 |
13.49 |
13.51 |
11.95 |
9.93 |
10.80 |
9.53 |
- |
6.67 |
| Noncontrolling Interest Sharing Ratio |
|
4.98% |
5.04% |
5.08% |
4.90% |
4.61% |
4.50% |
4.38% |
4.30% |
4.15% |
- |
4.38% |
| Liquidity Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Cash Flow Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Free Cash Flow to Firm (FCFF) |
|
122 |
307 |
315 |
652 |
-0.72 |
-629 |
-542 |
-1,499 |
-810 |
- |
-364 |
| Operating Cash Flow to CapEx |
|
1,690.92% |
278.68% |
706.27% |
530.37% |
727.58% |
909.79% |
516.12% |
0.00% |
1,067.64% |
- |
1,680.72% |
| Free Cash Flow to Firm to Interest Expense |
|
2.07 |
5.17 |
5.45 |
12.08 |
-0.01 |
-11.38 |
-10.36 |
-28.34 |
-13.93 |
- |
-7.32 |
| Operating Cash Flow to Interest Expense |
|
2.91 |
2.78 |
2.62 |
3.41 |
3.38 |
4.15 |
3.48 |
4.52 |
3.90 |
- |
4.33 |
| Operating Cash Flow Less CapEx to Interest Expense |
|
2.74 |
1.78 |
2.25 |
2.77 |
2.92 |
3.69 |
2.81 |
4.57 |
3.54 |
- |
4.07 |
| Efficiency Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Asset Turnover |
|
0.05 |
0.08 |
0.08 |
0.08 |
0.09 |
0.09 |
0.09 |
0.09 |
0.10 |
- |
0.10 |
| Fixed Asset Turnover |
|
0.07 |
0.11 |
0.12 |
0.12 |
0.13 |
0.14 |
0.14 |
0.14 |
0.15 |
- |
0.16 |
| Capital & Investment Metrics |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Invested Capital |
|
9,149 |
8,830 |
8,729 |
8,561 |
9,259 |
9,570 |
9,378 |
10,189 |
10,239 |
- |
9,896 |
| Invested Capital Turnover |
|
0.05 |
0.08 |
0.09 |
0.09 |
0.09 |
0.09 |
0.10 |
0.10 |
0.10 |
- |
0.11 |
| Increase / (Decrease) in Invested Capital |
|
-32 |
-261 |
-245 |
-538 |
110 |
740 |
650 |
1,628 |
980 |
- |
518 |
| Enterprise Value (EV) |
|
12,395 |
11,630 |
12,311 |
13,126 |
15,184 |
14,521 |
14,966 |
15,035 |
16,882 |
- |
17,603 |
| Market Capitalization |
|
7,474 |
6,820 |
7,459 |
8,315 |
10,494 |
10,037 |
10,732 |
10,606 |
12,455 |
- |
12,952 |
| Book Value per Share |
|
$14.98 |
$14.59 |
$14.22 |
$15.02 |
$16.32 |
$16.81 |
$16.82 |
$17.24 |
$17.07 |
- |
$17.56 |
| Tangible Book Value per Share |
|
$12.36 |
$11.96 |
$11.62 |
$12.41 |
$13.82 |
$14.42 |
$14.54 |
$15.01 |
$14.89 |
- |
$15.38 |
| Total Capital |
|
9,149 |
8,830 |
8,729 |
8,561 |
9,259 |
9,570 |
9,378 |
10,189 |
10,239 |
- |
9,896 |
| Total Debt |
|
5,291 |
5,067 |
5,028 |
4,661 |
4,858 |
4,839 |
4,446 |
5,000 |
4,995 |
- |
4,441 |
| Total Long-Term Debt |
|
5,272 |
5,047 |
5,008 |
4,590 |
4,858 |
4,839 |
4,446 |
5,000 |
4,995 |
- |
4,016 |
| Net Debt |
|
4,733 |
4,623 |
4,665 |
4,621 |
4,498 |
4,290 |
4,042 |
4,228 |
4,220 |
- |
4,388 |
| Capital Expenditures (CapEx) |
|
10 |
59 |
21 |
35 |
25 |
25 |
35 |
-2.31 |
21 |
- |
13 |
| Net Nonoperating Expense (NNE) |
|
-3.96 |
-9.76 |
1.14 |
-3.24 |
-5.73 |
-5.08 |
-4.03 |
-11 |
-15 |
- |
-4.81 |
| Net Nonoperating Obligations (NNO) |
|
5,291 |
5,067 |
5,028 |
4,661 |
4,858 |
4,839 |
4,446 |
5,000 |
4,995 |
- |
4,441 |
| Total Depreciation and Amortization (D&A) |
|
82 |
79 |
79 |
77 |
78 |
81 |
81 |
82 |
83 |
- |
88 |
| Earnings Adjustments |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Adjusted Basic Earnings per Share |
|
$0.37 |
$0.24 |
$0.27 |
$0.46 |
$0.43 |
$0.41 |
$0.34 |
$0.46 |
$0.60 |
$0.56 |
$0.47 |
| Adjusted Weighted Average Basic Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Adjusted Diluted Earnings per Share |
|
$0.37 |
$0.23 |
$0.27 |
$0.45 |
$0.42 |
$0.41 |
$0.33 |
$0.46 |
$0.59 |
$0.56 |
$0.47 |
| Adjusted Weighted Average Diluted Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Adjusted Basic & Diluted Earnings per Share |
|
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Adjusted Weighted Average Basic & Diluted Shares Outstanding |
|
244.99M |
245.30M |
247.10M |
257.84M |
269.95M |
281.84M |
289.40M |
295M |
295.53M |
295.57M |
297.80M |
| Normalized Net Operating Profit after Tax (NOPAT) |
|
74 |
45 |
79 |
111 |
124 |
114 |
111 |
123 |
172 |
- |
160 |
| Normalized NOPAT Margin |
|
40.48% |
25.31% |
41.64% |
55.81% |
55.99% |
51.98% |
47.17% |
53.52% |
61.09% |
- |
58.10% |
| Pre Tax Income Margin |
|
52.94% |
34.56% |
37.66% |
59.82% |
50.36% |
54.17% |
48.85% |
64.11% |
67.92% |
- |
57.89% |
| Debt Service Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| EBIT to Interest Expense |
|
1.56 |
0.84 |
1.26 |
2.15 |
2.06 |
2.07 |
2.13 |
2.52 |
3.00 |
- |
3.19 |
| NOPAT to Interest Expense |
|
1.53 |
0.79 |
1.22 |
2.11 |
2.00 |
2.02 |
2.07 |
2.45 |
2.93 |
- |
3.09 |
| EBIT Less CapEx to Interest Expense |
|
1.39 |
-0.15 |
0.89 |
1.50 |
1.59 |
1.61 |
1.46 |
2.57 |
2.64 |
- |
2.93 |
| NOPAT Less CapEx to Interest Expense |
|
1.36 |
-0.21 |
0.85 |
1.47 |
1.53 |
1.56 |
1.39 |
2.49 |
2.57 |
- |
2.83 |
| Payout Ratios |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
| Dividend Payout Ratio |
|
277.21% |
269.40% |
241.37% |
204.28% |
194.82% |
171.06% |
162.28% |
160.59% |
144.99% |
- |
127.50% |
| Augmented Payout Ratio |
|
277.21% |
269.40% |
241.37% |
204.28% |
194.82% |
171.06% |
162.28% |
160.59% |
144.99% |
- |
127.50% |
Key Financial Trends
Omega Healthcare Investors (NYSE: OHI) showed a mixed start to 2026, with solid operating cash flow and earnings, but also a smaller cash balance and continued reliance on debt and equity financing.
Over the last several years, OHI has generally produced steady quarterly profitability and operating cash flow, supported by recurring rental and related income. However, the balance sheet still shows meaningful leverage, and results continue to be influenced by investment gains/losses, credit loss provisions, and financing activity. The latest quarter shows the company remains capable of covering operations and dividends at a basic level, but there are signs of pressure in liquidity and capital structure.
- Operating cash flow remained strong in Q1 2026. OHI generated $215.5 million of net cash from operations, which compares favorably with recent quarters and supports its dividend-paying profile.
- Net income stayed healthy. Q1 2026 consolidated net income came in at $158.6 million, with $151.0 million attributable to common shareholders.
- Revenue growth remained intact year over year. Total revenue in Q1 2026 was $276.2 million, up from $234.6 million in Q1 2025 and ahead of most quarterly results over the past year.
- EPS improved versus the prior year. Basic EPS was $0.47 in Q1 2026, up from $0.34 in Q1 2025 and $0.41 in Q4 2024.
- Dividend coverage from operations appears manageable in the near term. Quarterly operating cash flow exceeded the $0.67 per-share dividend, though this does not fully remove long-term payout risk.
- Depreciation remains large but is typical for the business model. Q1 2026 depreciation expense was $84.1 million, continuing to weigh on accounting earnings but not on cash generation as much as a non-cash charge.
- OHI continues to carry substantial debt. Total debt was about $4.44 billion at March 31, 2026, including $425 million of short-term debt and $4.02 billion of long-term debt.
- Equity remains positive, but retained earnings are still deeply negative. Total common equity was $5.19 billion, while retained earnings were $(3.67) billion, reflecting years of cumulative distributions and accounting charges.
- Cash and equivalents dropped sharply from year-end. Cash and due from banks fell to $26.1 million in Q1 2026 from $737.2 million in Q3 2025, indicating much tighter liquidity.
- Investing activity consumed significant cash. Q1 2026 net cash used in investing activities was $(270.0) million, driven by $333.5 million of investment purchases.
Three-year trend summary: OHI’s quarterly earnings and operating cash flow have held up relatively well, with net income generally ranging from the low-$100 million area to the high-$100 million area in recent periods. That said, the company’s financial profile has also shown repeated dependence on financing transactions, including debt issuance, equity issuance, and debt repayment. The balance sheet has expanded and contracted, but leverage remains material, and liquidity can swing significantly quarter to quarter.
What stands out for investors: OHI still looks like a business that can produce cash and profits, but the margin for error is not huge. If operating performance softens, the combination of large debt, dividend obligations, and investment activity could become more of a constraint. On the other hand, continued strong cash from operations would help support the dividend and reduce pressure on the balance sheet.
05/31/26 10:50 PM ETAI Generated. May Contain Errors.